Business
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA
Nashville-based pharmaceutical company will acquire U.S. rights from Japan-based Kyowa Kirin SANCUSO® is an established, FDA-Approved Oncology Supportive Care
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"Nashville-based pharmaceutical company will acquire U.S. rights from Japan-based Kyowa Kirin\n SANCUSO® is an established, FDA-Approved Oncology Supportive Care Medicine\n\n\nNASHVILLE, Tenn. and BEDMINSTER, N.J., Jan. 4, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company focused on discovering and delivering novel medicines.\n\n \n \n \n \n \n \n\n \nSANCUSO is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in SANCUSO, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient's skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (CINV). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.\n\"In 2020 there were nearly two million new cases of cancer in the U.S. and each year over half a million Americans undergo chemotherapy, with many suffering from the side effects of their treatment. With SANCUSO, patients are given a simple, easy-to-apply preventative solution that doesn't require swallowing any pills – which can be difficult for patients experiencing nausea,\" said A.J. Kazimi, chief executive officer at Cumberland Pharmaceuticals. \"We are honored to take responsibility for the brand and introduce it through our commercial organization, ensuring that it is delivered to the patients who need it.\"\nUnder the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO and will assume full commercial responsibility for the product – including its marketing, promotion, distribution, manufacturing and medical support activities. Net sales of the brand in the U.S. were over $14 million in 2020. The financial terms of the acquisition include ...